Mariko Tsukagoshi

Dr. Mariko Tsukagoshi

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
MTMariko Tsukagoshi
Mariko Tsukagoshi
KAKenichiro Araki
Kenichiro Araki
TITakamichi Igarashi
Takamichi Igarashi
NINorihiro Ishii
Norihiro Ishii
SKShunsuke Kawai
Shunsuke Kawai
KSKen Shirabe
Ken Shirabe
Increasing evidence suggests that nutritional indices, including the geriatric nutritional risk index (GNRI) and prognostic nutritional index (PNI), are predictors of poor prognosis in patients with hepatocellular carcinoma (HCC). Hence, this study aimed to explore the value of the GNRI and PNI in evaluating postoperative prognosis in patients with HCC, particularly regarding its recurrence patterns. We performed a retrospective analysis of 203 patients with HCC who underwent initial hepatic resection. Patients were divided into two groups according to the GNRI (cutoff: 98) and PNI (cutoff: 45). The GNRI and PNI were significantly associated with body composition (body mass index and skeletal muscle mass index), hepatic function (Child-Pugh Score), tumor factors (tumor size and microvascular invasion), and perioperative factors (blood loss and postoperative hospitalization). Patients with a low PNI or low GNRI had significantly worse overall survival (OS) and recurrence-free survival. Patients with early recurrence had lower PNI and GNRI scores than those without early recurrence. Patients with extrahepatic recurrence had lower PNI and GNRI scores than those without extrahepatic recurrence. The PNI and GNRI might be useful in predicting the prognosis and recurrence patterns of patients with HCC after hepatic resection.

26 November 2015 in Cancer Science
Verified
Journal Article
Open access
PDF file
MTMariko Tsukagoshi
Mariko Tsukagoshi
SWSatoshi Wada
Satoshi Wada
TYTakehiko Yokobori
Takehiko Yokobori
BABolag Altan
Bolag Altan
NINorihiro Ishii
Norihiro Ishii
HKHiroyuki Kuwano
Hiroyuki Kuwano
The natural killer group 2 member D (NKG2D) receptor and its ligands are important mediators of immune responses to tumors. NKG2D ligands are overexpressed in several malignant tumor types; however, the prognostic value of these ligands is unclear. Here, we aimed to elucidate the role of NKG2D ligands in extrahepatic cholangiocarcinoma (EHCC). We therefore investigated the expression of the NKG2D receptor and its ligands MHC class I chain‐related proteins A and B (MICA/B), unique long 16 binding protein (ULBP) 1, and ULBP2/5/6 in resected specimens from 82 patients with EHCC. All NKG2D ligands were highly expressed in EHCC. High expression of MICA/B or ULBP2/5/6 correlated with overall and disease‐free survival. In contrast, high expression of ULBP1 was significantly associated with improved overall survival, but not disease‐free survival. Concurrent high expression of multiple NKG2D ligands revealed significantly better overall and disease‐free survival than that observed with the overexpression of any one NKG2D ligand. Co‐expression of multiple NKG2D ligands was an independent prognostic indicator of improved survival. Furthermore, co‐overexpression of multiple NKG2D ligands was significantly correlated with high expression of the NKG2D receptor. Inhibiting interactions between multiple NKG2D ligands and the NKG2D receptor might be a promising approach for controlling cancer progression and improving patient prognosis in EHCC.

25 April 2023 in Annals of Gastroenterological Surgery
Verified
Journal Article
Open access
MTMariko Tsukagoshi
Mariko Tsukagoshi
AWAkira Watanabe
Akira Watanabe
KAKenichiro Araki
Kenichiro Araki
NINorihiro Ishii
Norihiro Ishii
KHKei Hagiwara
Kei Hagiwara
KSKen Shirabe
Ken Shirabe
Aim: This study aimed to evaluate the usefulness of the serum creatinine/cystatin C (Cr/CysC) ratio as a prognostic factor after pancreatic surgery in patients with pancreatic cancer.Methods: We retrospectively analyzed the data of 88 patients with pancreatic ductal carcinoma who underwent pancreatic surgery from January 2017 to December 2020. CysC measured from frozen serum samples and circulating Cr levels were used to calculate the Cr/CysC ratio. The cutoff value of the Cr/CysC ratio was determined using receiver operating characteristic curves. Cox proportional hazards model analysis and survival curves were applied to identify the prognostic factors.Results: The optimal cutoff value of the Cr/CysC ratio for predicting mortality after surgery was 1.05. This study included 20 (22.7%) and 68 (77.3%) patients with high and low Cr/CysC ratios, respectively. The low Cr/CysC ratio was significantly associated with female sex (p = 0.020) and higher levels of C‐reactive protein (p = 0.020). The postoperative length of stay was significantly longer in patients with low Cr/CysC rates (p = 0.044). Patients with low Cr/CysC ratio showed poorer prognosis in relapse‐free survival (hazard ratio [HR] = 3.33; 95% confidence interval [CI]: 1.54–4.20; p = 0.002) and overall survival (HR = 2.52, 95% CI: 1.04–6.10, p = 0.041), respectively, which were significantly worse than in those with high Cr/CysC ratios (p = 0.003 and 0.049, respectively).Conclusion: The Cr/CysC ratio could be a useful screening tool for predicting the prognosis of patients with pancreatic ductal carcinoma undergoing pancreatic surgery.

2 July 2024 in International Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
MTMariko Tsukagoshi
Mariko Tsukagoshi
KAKenichiro Araki
Kenichiro Araki
KSKen Shirabe
Ken Shirabe

15 August 2021 in Cancers
Verified
Journal Article
Open access
PDF file
MTMariko Tsukagoshi
Mariko Tsukagoshi
NHNorifumi Harimoto
Norifumi Harimoto
KAKenichiro Araki
Kenichiro Araki
NKNorio Kubo
Norio Kubo
AWAkira Watanabe
Akira Watanabe
KSKen Shirabe
Ken Shirabe
The efficacy and prognosis of adjuvant chemotherapy for resected pancreatic cancer remain unclear. We investigated the utility and risk factors of S-1 adjuvant chemotherapy in patients with pancreatic cancer undergoing pancreatectomy. This study comprised 80 patients, including 58 patients who received S-1 adjuvant chemotherapy. Skeletal muscle loss was defined using cutoff values of skeletal muscle mass index. In total, 16 (20%) octogenarian patients underwent pancreatectomy. Skeletal muscle loss was present in 56 (70%) patients. The entire course of S-1 adjuvant chemotherapy for 6 months was completed in 33 patients (41%). S-1 adjuvant chemotherapy <6 months was an independent prognostic indicator of poor overall survival. Patients who completed S-1 adjuvant chemotherapy exhibited significantly longer overall and relapse-free survival rates than those did not complete the chemotherapy (p < 0.0001 and p = 0.0003, respectively). Being an octogenarian and skeletal muscle loss were independent variables associated with the discontinuation of S-1 adjuvant chemotherapy. Finally, the S-1 adjuvant chemotherapy rates were 6.3% (1/16) and 28.6% (16/56) in octogenarian patients and those with skeletal muscle loss, respectively. S-1 adjuvant chemotherapy completion was associated with improved prognosis in patients with pancreatic cancer. Skeletal muscle loss and octogenarian status predicted the failure of S-1 adjuvant chemotherapy completion.

1 April 2018 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
MTMariko Tsukagoshi
Mariko Tsukagoshi
KAKenichiro Araki
Kenichiro Araki
FSFumiyoshi Saito
Fumiyoshi Saito
NKNorio Kubo
Norio Kubo
AWAkira Watanabe
Akira Watanabe
HKHiroyuki Kuwano
Hiroyuki Kuwano